PEDRO PIEDRA to Influenza Vaccines
This is a "connection" page, showing publications PEDRO PIEDRA has written about Influenza Vaccines.
Connection Strength
2.939
-
Live Attenuated Influenza Vaccine: Will the Phoenix Rise Again? Pediatrics. 2019 02; 143(2).
Score: 0.421
-
Influenza A(H5N1) vaccines: are we better prepared for the next pandemic? J Infect Dis. 2014 Jan 01; 209(1):1-3.
Score: 0.293
-
Direct and indirect effectiveness of influenza vaccination delivered to children at school preceding an epidemic caused by 3 new influenza virus variants. J Infect Dis. 2010 Dec 01; 202(11):1626-33.
Score: 0.238
-
Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics. 2007 Sep; 120(3):e553-64.
Score: 0.191
-
Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics. 2005 Sep; 116(3):e397-407.
Score: 0.167
-
Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine. 2005 Feb 18; 23(13):1540-8.
Score: 0.161
-
Immunization against viral respiratory disease: a review. Pediatr Infect Dis J. 2004 Nov; 23(11 Suppl):S254-61.
Score: 0.157
-
Sustained Within-season Vaccine Effectiveness Against Influenza-associated Hospitalization in Children: Evidence From the New Vaccine Surveillance Network, 2015-2016 Through 2019-2020. Clin Infect Dis. 2023 02 08; 76(3):e1031-e1039.
Score: 0.140
-
Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children. Pediatrics. 2002 Oct; 110(4):662-72.
Score: 0.136
-
Safety of the trivalent, cold-adapted influenza vaccine (CAIV-T) in children. Semin Pediatr Infect Dis. 2002 Apr; 13(2):90-6.
Score: 0.132
-
Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and Vaccine Effectiveness by Genetic Group, 2014-2015. J Infect Dis. 2016 10 01; 214(7):1010-9.
Score: 0.087
-
Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type During 2013-2014 in the United States. J Infect Dis. 2016 May 15; 213(10):1546-56.
Score: 0.085
-
Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type. J Infect Dis. 2015 May 15; 211(10):1529-40.
Score: 0.079
-
Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis. 2014 Feb; 58(3):319-27.
Score: 0.074
-
[Universal immunisation against influenza in paediatrics, yes or no?]. An Pediatr (Barc). 2013 Oct; 79(4):261.e1-261.e11.
Score: 0.071
-
Studies on reactogenicity and immunogenicity of attenuated bivalent cold recombinant influenza type A (CRA) and inactivated trivalent influenza virus (TI) vaccines in infants and young children. Vaccine. 1993; 11(7):718-24.
Score: 0.069
-
Safety of the intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trial. Pediatr Infect Dis J. 2008 May; 27(5):444-52.
Score: 0.050
-
Cost-effectiveness of live-attenuated influenza vaccine, trivalent in preventing influenza in young children attending day-care centres. Vaccine. 2007 Nov 19; 25(47):8010-20.
Score: 0.048
-
Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004. Vaccine. 2007 May 16; 25(20):4038-45.
Score: 0.046
-
Safety of cold-adapted live influenza vaccine. Pediatr Infect Dis J. 2004 Jun; 23(6):593-4; author reply 594.
Score: 0.038
-
Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children. Arch Pediatr Adolesc Med. 2004 Jan; 158(1):65-73.
Score: 0.037
-
Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures. Am J Epidemiol. 2003 Aug 15; 158(4):305-11.
Score: 0.036
-
Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis. 2000 Mar; 181(3):1133-7.
Score: 0.028
-
Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr. 2000 Feb; 136(2):168-75.
Score: 0.028
-
The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med. 1998 May 14; 338(20):1405-12.
Score: 0.025
-
Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children. J Infect Dis. 1998 May; 177(5):1394-7.
Score: 0.025
-
Influenza virus infections in infants. Pediatr Infect Dis J. 1997 Nov; 16(11):1065-8.
Score: 0.024
-
Cytotoxic T lymphocyte responses of infants after natural infection or immunization with live cold-recombinant or inactivated influenza A virus vaccine. J Med Virol. 1996 Oct; 50(2):105-11.
Score: 0.022
-
Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza Vaccine Investigators Group. J Infect Dis. 1996 Jun; 173(6):1313-9.
Score: 0.022
-
Prevention and treatment of respiratory syncytial virus and parainfluenza viruses in immunocompromised patients. Am J Med. 1997 Mar 17; 102(3A):61-70; discussion 75-6.
Score: 0.006